Compare Cronos Group Inc (CRON) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Cronos Group Inc trades at $3.22 (market cap $1.18B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.88 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 21.4× Cronos Group Inc's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| CRON | RPRX | |
|---|---|---|
Market Cap | $1.18B | $25.27B |
Volume | 968,037 | 3,671,183 |
Sector | Health | Health |
52-Week High | $3.55 | $63.96 |
52-Week Low | $2.30 | $35.44 |
Typical Hold Time | 22 Days | 1 Days |
Enterprise Value | $387.62M | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.23, down 0.31% with a bearish technical signal. Recent earnings show volatility with Q2 2026 beating expectations ($0.09 vs $0.01) but Q4 2025 missing. Revenue grew from $118M (2024) to $147M (2025), though net income turned negative at -$9M. The company maintains strong liquidity with $827M cash and no debt, highlighted in recent investor day presentations.
Outlook is mixed: analyst consensus leans Hold (60%) with cautious optimism on international expansion and margin improvements. Key risks include sustained negative cash flow (-$67M in 2025) and competitive pressures. Upside hinges on execution of growth initiatives in Canada and Europe, with profitability projections for 2026.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
